Introduction: In polytrauma patients with AKI continuous venovenous hemodialysis (CVVHD) with medium cutoff membrane filters is commonly adopted to increase the removal of both myoglobin and inflammatory mediators, but its impact on increasing molecular weight markers of inflammation and cardiac damage is debated. Methods: Twelve critically ill patients with rhabdomyolysis (4 burns and 8 polytrauma patients) and early AKI requiring CVVHD with EMIc2 filter were tested for 72 h on serum and effluent levels for NT-proBNP, procalcitonin (PCT), myoglobin, C-reactive protein (CRP), alpha1-glycoprotein, albumin, and total protein. Results: The sieving coefficients (SCs) for proBNP and myoglobin were as higher as 0.5 at the start, decreased to 0.3 at the 2nd h, and then slowly declined to the final value of 0.25 and 0.20 at the 72nd h, respectively. PCT showed a negligible SC at the 1st h, a peak of 0.4 at the 12th h, and a final value of 0.3. SCs for albumin, alpha1-glycoprotein, and total protein were negligible. A similar trend was observed for the clearances (17–25 mL/min for proBNP and myoglobin; 12 mL/for PCT; <2 mL/min for albumin, alpha1-glycoprotein, and total protein). No correlation was found between systemic determinations and filter clearances of proBNP, PCT, and myoglobin. Net fluid loss/hour during CVVHD positively correlated with systemic myoglobin for all patients and NT-proBNP in the burn patients. Conclusion: CVVHD with EMiC2 filter showed low clearances for NT-proBNP and procalcitonin. CVVHD did not significantly affect the serum levels of these biomarkers, which could be adopted in the clinical management of early CVVHD patients.

Keywords:
Medium cutoff filter, NT-proBNP, Procalcitonin, Myoglobin, Continuous renal replacement therapy
1.
Søvik S, Isachsen MS, Nordhuus KM, Tveiten CK, Eken T, Sunde K, et al. Acute kidney injury in trauma patients admitted to the ICU: a systematic review and meta-analysis. Intensive Care Med. 2019;45(4):407–19.
2.
Folkestad T, Brurberg KG, Nordhuus KM, Tveiten CK, Guttormsen AB, Os I, et al. Acute kidney injury in burn patients admitted to the intensive care unit: a systematic review and meta-analysis. Crit Care. 2020;24(1):2–11.
3.
Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care. 2014;18(3):224.
4.
Bosch X, Poch EGJ, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.
5.
Villa G, Neri M, Bellomo R, Cerda J, De Gaudio AR, De Rosa S, et al. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care. 2016;20(1):283–11.
6.
Ronco C, Bellomo R. Acute renal failure and multiple organ dysfunction in the ICU: from Renal Replacement Therapy (RRT) to Multiple Organ Support Therapy (MOST). Int J Artif Organs. 2002;25(8):733–47.
7.
Mariano F, Hollo’ Z, Depetris N, Malvasio V, Mella A, Bergamo D, et al. Coupled-plasma filtration and adsorption for severe burn patients with septic shock and acute kidney injury treated with renal replacement therapy. Burns. 2020;46(1):190–8.
8.
Dahaba AA, Elawady GA, Rehak PH, List WF. Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care. 2002;30(3):269–74.
9.
Caldini A, Chelazzi C, Terreni A, Biagioli T, Giannoni C, Villa G, et al. Is procalcitonin a reliable marker of sepsis in critically ill septic patients undergoing continuous veno-venous hemodiafiltration with “High Cut-Off” membranes (HCO-CVVHDF)? Clin Chem Lab Med. 2013;51(11):e261–e263.
10.
Level C, Chauveau P, Guisset O, Cazin MC, Lasseur C, Gabinsky C, et al. Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure. Crit Care. 2003;7(6):R160–6.
11.
Meisner M, Hüttemann E, Lohs T, Kasakov L, Reinhart K. Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patient. Eur J Anaesth. 2000;17:655–71.
12.
Meisner M, Hüttemann E, Lohs T, Kasakov L, Reinhart K. Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients. Shock. 2001;15(3):171–5.
13.
Lumlertgul N, Hall A, Camporota L, Crichton S, Ostermann M. Clearance of inflammatory cytokines in patients with septic acute kidney injury during renal replacement therapy using the EMiC2 filter (Clic-AKI study). Crit Care. 2021;25(1):39–11.
14.
Chen H, Wu B, Gong D, Liu Z. Fluid overload at start of continuous renal replacement therapy is associated with poorer clinical condition and outcome: a prospective observational study on the combined use of bioimpedance vector analysis and serum N-terminal pro-B-type natriuretic pep. Crit Care. 2015;19(1):1–8.
15.
Yin L, Han Z, Zhang Q, Xie J, Wang C, Zhao L. The effect of hemodialysis on N-terminal pro-brain natriuretic peptide: a systematic review and meta-analysis. Am J Emerg Med. 2021;44:244–9.
16.
Ceccarelli G, Alessandri F, Sargentini V, D’Alessandro MD, Spaziante M, Bachetoni A, et al. Impact of Continuous Renal Replacement Therapy (CRRT) and other extracorporeal support techniques on procalcitonin guided antibiotic therapy in critically ill patients with septic shock. Clin Chem Lab Med. 2019;57(5):E86–7.
17.
Falcone M, Tiseo G, Menichetti F. Interpreting procalcitonin in patients undergoing hemodialysis: a reliable or a misleading marker? Intern Emerg Med. 2021;16(1):11–3.
18.
Harm S, Schildböck C, Hartmann J. Cytokine removal in extracorporeal blood purification: an in vitro study. Blood Purif. 2020;49(1–2):33–43.
19.
Mariano F, Inguaggiato P, Pozzato M, Turello E, David P, Berutti S, et al. Increase of continuous treatments and regional citrate anticoagulation during renal replacement therapy in the ICUs of the north-west of Italy from 2007 to 2015. Minerva Urol Nephrol. 2022 Mar 11.
20.
Mariano F, Morselli M, Holló Z, Agostini F, Stella M, Biancone L. Citrate pharmacokinetics at high levels of circuit citratemia during coupled plasma filtration adsorption. Nephrol Dial Transpl. 2015;30(11):1911–9.
21.
Mariano F. Continuous Renal Replacement Therapy (CRRT) in intensive care. In: Allaria B, editor. Practical issues in anesthesia and intensive care 2013. Milan: Springer-Verlag; 2014. p. 131–44.
22.
Zhang J, Tian J, Sun H, Digvijay K, Neri M, Bhargava V, et al. How does continuous renal replacement therapy affect septic acute kidney injury? Blood Purif. 2018;46(4):326–31.
23.
Cantaluppi V, Dellepiane S, Tetta C, Mariano F, Segoloni G. Humoral mediators in sepsis. In: Ronco C, Bellomo R, Kellum JA, Ricci Z, editors. Critical care nephrology. 3rd ed. London: Elsevier Inc.; 2019. p. 109–13.
24.
Mariano F, Gangemi EN, Bergamo D, Hollo Z, Stella M, Triolo G. Burns and acute kidney failure. In: Jorres A, Ronco C, Kellum JA, editors. Management of acute kidney problems. 1st ed. Berlin, Heidelberg: Springer-Verlag; 2010. p. 429–38.
25.
Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28(2):458–61.
26.
Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C. Cytokine removal with high cut-off membrane: review of literature. Blood Purif. 2014;38(3–4):167–73.
27.
Kade G, Literacki S, Rzeszotarska A, Niemczyk S, Lubas A. Removal of procalcitonin and selected cytokines during continuous veno-venous hemodialysis using high cutoff hemofilters in patients with sepsis and acute kidney injury. Blood Purif. 2018;46(2):153–9.
28.
Kandi M, Brignardello-Petersen R, Couban R, Wu C, Nesrallah G. Effects of medium cut-off versus high-flux hemodialysis membranes on biomarkers: a systematic review and meta-analysis. Can J Kidney Health Dis. 2022;9(9):20543581211067090.
29.
Meisner M, Schmidt J, Hüttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med. 2000;26(Suppl 2):S212–6.
30.
Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol. 2001;18(2):79–87.
31.
Harrison TG, Shukalek CB, Hemmelgarn BR, Zarnke KB, Ronksley PE, Iragorri N, et al. Association of NT-proBNP and BNP with future clinical outcomes in patients with ESKD: a systematic review and meta-analysis. Am J Kidney Dis. 2020;76(2):233–47.
32.
Yang WL, Fahim M, Johnson DW. Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease. Clin Biochem. 2020;83:1–11.
33.
Ronco C, Kaushik M, Valle R, Aspromonte N, Peacock WF 4th. Diagnosis and management of fluid overload in heart failure and cardio-renal syndrome: the “5B ” approach. Semin Nephrol. 2012;32(1):129–41.
34.
Paratz JD, Lipman J, Boots RJ, Muller MJ, Paterson DL. A new marker of sepsis post burn injury? Crit Care Med. 2014 Sep;42(9):2029–36.
35.
Kroll MH, Srisawasdi P. The clearance of BNP modeled using the NT-proBNP-BNP relationship. Biosystems. 2007;88(1–2):147–55.
36.
Panizo N, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, Moreno JA. Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury. Kidney Blood Press Res. 2015;40(5):520–32.
37.
Tarazona V, Figueiredo S, Hamada S, Pochard J, Haines RW, Prowle JR, et al. Admission serum myoglobin and the development of acute kidney injury after major trauma. Ann Intensive Care. 2021;11(1):140.
38.
Weidhase L, de Fallois J, Haußig E, Kaiser T, Mende M, Petros S. Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Crit Care. 2020;24(1):644.
39.
Vincent JL. Recent negative clinical trials in septic patients: maybe a good thing? Minerva Anestesiol. 2015;81(2):122–4.
40.
Bagshaw SM, Chakravarthi MR, Ricci Z, Tolwani A, Neri M, De Rosa S, et al. Precision continuous renal replacement therapy and solute control. Blood Purif. 2016;42(3):238–47.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.